ArticleEuropean thyroid journal2022
Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association.
Article in European thyroid journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06413043 (Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy), which is not on this map. Cited by 65 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy: A Randomized Control Trial
Who cites it
65 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Association of IL-6 and IL-17 with thyroid eye disease.Frontiers in endocrinology · 2026Pooled it
- Association between serum immunoglobulin G4 levels and Graves' ophthalmopathy: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Meibomian gland dysfunction in patients with thyroid-associated ophthalmopathy: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials.International journal of clinical practice · 2023Pooled it
- Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.The Journal of clinical endocrinology and metabolism · 2023Trial
- Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2023Trial
- Relationship between serum IgG4 levels and clinical activity of ophthalmopathy in Graves' disease.BMC ophthalmology · 2026Article
- Gut Microbial Metabolite Indole-3-Acetic Acid Exerts Protective Effects by Regulating Orbital Fibroblast Fibrosis in Thyroid Eye Disease.Investigative ophthalmology & visual science · 2026Article
- Impacts of Thyroid Eye Disease (TED), Beyond the Signs and Symptoms: Results from the ElevaTED Patient Survey.Ophthalmology and therapy · 2026Article
- Validation and Development of Claims-Based Algorithms for Identifying Thyroid Eye Disease Using the IRIS Registry-Komodo Linked Database.Journal of clinical medicine · 2026Article
- Evaluating and enhancing the performance of large language models in thyroid eye disease through customization and Chain-of-Thought strategies.Scientific reports · 2026Article
- Impacts of physical, metabolic, and immunological factors on the exophthalmometry values of a contemporary Japanese population with/without Graves' disease.Endocrine journal · 2026Article
- Sequential sensitivity analysis of multimodal large language models for rare orbital disease detection.Communications medicine · 2026Article
- What has changed in thyroid eye disease in the last five years (2020-2025).European thyroid journal · 2026Review
- Natural product-based interventions for thyroid disorders: mechanisms and applications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Quantitative intravoxel incoherent motion diffusion-weighted imaging histogram profiling identifies diffusion biomarkers for active thyroid-associated ophthalmopathy.BMC medical imaging · 2026Article
- Orbital computed tomography biomarkers for the assessment of activity of Thyroid Eye Disease.PloS one · 2026Article
- Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Cytokines and drugs targeting cytokines in Graves' disease and thyroid eye disease.Frontiers in immunology · 2026Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid eye disease (TED) remains challenging for clinicians to evaluate and manage. Novel therapies have recently emerged, and their specific roles are still being determined. Most patients with TED develop eye manifestations while being treated for hyperthyroidism and under the care of endocrinologists. Endocrinologists, therefore, have a key role in diagnosis, initial management, and selection of patients who require referral to specialist care. Given that the need for guidance to endocrinologists charged with meeting the needs of patients with TED transcends national borders, and to maximize an international exchange of knowledge and practices, the American Thyroid Association and European Thyroid Association joined forces to produce this Consensus Statement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.